Kairos Pharma Ltd. Announces Peer Reviewed Publication Highlighting Potentially Groundbreaking Discovery in Overcoming Drug Resistance in Non-Small Cell Lung Cancer

Rhea-AI Summary

Kairos Pharma (NYSE American: KAPA) has published peer-reviewed research revealing a potential breakthrough in treating drug resistance in non-small cell lung cancer (NSCLC). The study, published in Drug Resistance Updates, demonstrates that CD105 (endoglin) plays a important role in resistance to osimertinib, a frontline NSCLC treatment.

The research shows that ENV105 (carotuximab), a CD105-neutralizing antibody, successfully restored treatment sensitivity to EGFR-targeted therapies in preclinical models. The combination of osimertinib with ENV105 reinstated susceptibility to EGFR inhibition through metabolic reprogramming and enhanced chromatin accessibility.

The global NSCLC treatment market is projected to reach $45 billion by 2030. Kairos Pharma is currently conducting clinical trials to evaluate this therapy in EGFR-driven lung cancer patients.

Positive

• Breakthrough discovery in addressing drug resistance for NSCLC treatment
• Successful preclinical results showing ENV105's ability to restore treatment sensitivity
• Large market opportunity with NSCLC treatment market projected at $45B by 2030
• Technology demonstrates potential applications across multiple cancers (prostate, breast, colon)

Negative

• Clinical trial results still pending - no proven efficacy in humans yet
• Current findings to preclinical models

Insights

Biotechnology Analyst

Kairos Pharma's peer-reviewed publication reveals a significant scientific advancement addressing a critical challenge in oncology - drug resistance in EGFR-mutant non-small cell lung cancer. The identification of CD105 (endoglin) as a resistance mechanism to osimertinib represents a novel finding with clinical implications.

The preclinical data demonstrating ENV105's ability to restore sensitivity to EGFR inhibitors through metabolic reprogramming and enhanced chromatin accessibility provides a clear mechanistic rationale. Particularly noteworthy is the potential broader application across multiple cancer types including prostate, breast, and colon cancers, suggesting a platform approach rather than a single-indication opportunity.

This publication adds scientific credibility to Kairos's clinical development program. However, investors should recognize the substantial gap between preclinical findings and clinical success. The ongoing clinical trials for EGFR-driven lung cancer will be the true validation of this approach's commercial potential.

With the NSCLC market projected to reach $45 billion by 2030 and drug resistance remaining an unmet need, successful clinical translation could position ENV105 as a valuable companion therapy to existing standards of care. The publication strengthens Kairos's scientific foundation while we await the more definitive clinical trial results.

LOS ANGELES--(BUSINESS WIRE)-- Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announces a peer-reviewed publication highlighting a potentially significant breakthrough in addressing drug resistance to EGFR-targeted therapies for non-small cell lung cancer (NSCLC) patients. Recent findings published in Drug Resistance Updates highlight the critical role of CD105 (endoglin) in mediating resistance to osimertinib, a frontline treatment for EGFR-mutant NSCLC. The study, titled, “CD105 blockade restores osimertinib sensitivity in drug-resistant EGFR-mutant non-small cell lung cancer,” demonstrated that CD105 expression is upregulated as a mechanism of therapy resistance, correlating with poor prognosis in patients.

“We believe our latest findings represent a paradigm shift in overcoming resistance to EGFR-targeted therapies in NSCLC,” said Neil Bhowmick, Ph.D., Kairos Pharma Chief Scientific Officer. “Revealing this mechanism-of-action underscores our commitment to advancing precision oncology and bringing innovative therapies to patients in need.”

In preclinical models, targeting CD105 with ENV105 (carotuximab), a CD105-neutralizing antibody successfully restored treatment sensitivity to EGFR-targeted therapies. Notably, combining osimertinib with ENV105 reinstated susceptibility to EGFR inhibition through metabolic reprogramming and enhanced chromatin accessibility. These findings confirm the efficacy of this novel combination therapy strategy in overcoming drug resistance in this model of non-small cell lung cancer.

Dr. John Yu, CEO, stated, “These findings in lung cancer corroborate data in prostate cancer, breast cancer and colon cancer, that point to CD105 being a central mechanism of cancer drug resistance. We believe ENV105 can reverse this resistance in cancer models, and our clinical trials are designed to definitively demonstrate its potential impact.”

The global NSCLC treatment market is projected to reach $45 billion by 2030, driven by advancements in targeted therapies. However, drug resistance remains a major challenge. The ability of ENV105 to enhance EGFR-targeted therapy effectiveness positions it as a high-value asset in next-generation oncology treatment. Kairos Pharma is currently evaluating this transformative cancer therapy in ongoing clinical trials for EGFR-driven lung cancer patients. The study can be accessed here.

About Kairos Pharma Ltd.

Based in Los Angeles, California, Kairos Pharma Ltd. (NYSE American: KAPA) is at the forefront of oncology therapeutics, utilizing structural biology to overcome drug resistance and immune suppression in cancer. Our lead candidate, ENV105, is an antibody that targets CD105 – a protein identified as a key driver of resistance to various cancer treatments. Elevation of CD105 in response to standard therapy results in resistance and disease relapse. ENV105 aims to reverse drug resistance by targeting CD105 and restore the effectiveness of standard therapies across multiple cancer types. Currently, ENV105 is in a Phase 2 clinical trial for castrate-resistant prostate cancer and a Phase 1 trial for lung cancer aimed at addressing significant unmet medical needs. For more information, visit kairospharma.com.

CAUTIONARY STATEMENT CONCERNING FORWARD-LOOKING STATEMENTS

This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. You can identify forward-looking statements as those that are not historical in nature, particularly those that use terminology such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential” or “hopes” or the negative of these or similar terms. The reader is cautioned not to rely on these forward-looking statements. If underlying assumptions prove inaccurate, or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Kairos Pharma. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance. In evaluating these forward-looking statements, you should consider various factors, including: our expectations regarding the success and/or completion of our Phase 1 and Phase 2 clinical trials; our success in completing newly initiated clinical trials, commence new trials, and obtain regulatory approval following the conclusion of such trials; challenges and uncertainties inherent in product research and development; and the uncertainty regarding future commercial success. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking statements discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties and assumptions about us, including those described in Kairos Pharma’s prospectus and our other filings made with the SEC. We are not obligated to publicly update or revise any forward-looking statement, and Kairos Pharma is not required to update any forward-looking statement as a result of new information or future events or developments, except as required by U.S. federal securities laws.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250320049401/en/

CORE IR

Louie Toma

investors@kairospharma.com

Source: Kairos Pharma, Ltd

FAQ

What breakthrough did Kairos Pharma (KAPA) announce for non-small cell lung cancer treatment?

Kairos Pharma discovered that CD105 (endoglin) mediates resistance to osimertinib in NSCLC, and their antibody ENV105 can potentially overcome this resistance when used in combination therapy.

How does Kairos Pharma's ENV105 work in treating NSCLC drug resistance?

ENV105 (carotuximab) is a CD105-neutralizing antibody that restores sensitivity to EGFR-targeted therapies through metabolic reprogramming and enhanced chromatin accessibility.

What is the market potential for KAPA's NSCLC treatment breakthrough?

The global NSCLC treatment market is expected to reach $45 billion by 2030, with ENV105 positioned as a potential key asset in next-generation oncology treatment.

What stage is Kairos Pharma's (KAPA) ENV105 cancer therapy currently in?

ENV105 is currently being evaluated in clinical trials for EGFR-driven lung cancer patients.

How does KAPA's discovery impact current NSCLC treatment approaches?

The discovery represents a paradigm shift in addressing resistance to EGFR-targeted therapies, potentially improving treatment outcomes for NSCLC patients.